RT Journal Article SR Electronic T1 BRAF mutation testing of MSI CRCs in Lynch syndrome diagnostics: performance and efficiency according to patient’s age JF medRxiv FD Cold Spring Harbor Laboratory Press SP 19009274 DO 10.1101/19009274 A1 Bläker, Hendrik A1 Haupt, Saskia A1 Morak, Monika A1 Holinski-Feder, Elke A1 Arnold, Alexander A1 Horst, David A1 Sieber-Frank, Julia A1 Seidler, Florian A1 von Winterfeld, Moritz A1 Alwers, Elizabeth A1 Chang-Claude, Jenny A1 Brenner, Hermann A1 Roth, Wilfried A1 Engel, Christoph A1 Löffler, Markus A1 Möslein, Gabriela A1 Schackert, Hans-Konrad A1 Weitz, Jürgen A1 Perne, Claudia A1 Aretz, Stefan A1 Hüneburg, Robert A1 Schmiegel, Wolff A1 Vangala, Deepak A1 Rahner, Nils A1 Steinke-Lange, Verena A1 Heuveline, Vincent A1 von Knebel Doeberitz, Magnus A1 Ahadova, Aysel A1 Hoffmeister, Michael A1 Kloor, Matthias A1 the German Consortium for Familial Intestinal Cancer YR 2019 UL http://medrxiv.org/content/early/2019/10/16/19009274.abstract AB Background and aims BRAF V600E mutations have been reported to be associated with sporadic microsatellite-unstable (MSI) colorectal cancer (CRC), while rarely detected in CRCs of Lynch syndrome (LS) patients. Therefore, current international diagnostic guidelines recommend somatic BRAF mutation testing in MLH1-deficient MSI CRC patients to exclude LS. As sporadic BRAF-mutant MSI CRC is a disease of the elderly, while LS-associated CRC usually occurs at younger age, we hypothesized that the efficacy of BRAF testing in LS diagnostics may be age-dependent.Methods We systematically compared the prevalence of BRAF V600E mutations in LS-associated CRCs and MSI CRCs from population-based cohorts in different age groups as available from published studies, databases, and population-based patient cohorts. Cost calculations and sensitivity analysis of the BRAF testing for exclusion of LS was performed.Results Among 969 MSI CRCs from LS mutation carriers from the literature and German HNPCC Consortium, 15 (1.6%, 95% CI: 0.9-2.6%) harbored BRAF mutations. 6/7 LS patients with BRAF-mutant CRC and reported age were <50 years. Among unselected MSI CRCs, 44.8% (339/756) harbored BRAF mutations, 92.3% (313/339) of which were detected in patients >60 years. In MSI CRC patients <50, BRAF mutations were detected only in 0.6% (2/339), and the inclusion of BRAF testing led to increased costs and higher risk of missing LS patients (1.2%) compared to other age groups.Conclusion BRAF testing in patients <50 years is cost-inefficient and carries the highest risk of missing LS patients among different age groups. We suggest direct referral of MSI CRC patients <50 years to genetic counseling without prior BRAF testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by Wilhelm Sander Foundation (2016.056.1), and German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; KFO227, KL2354).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAll relevant data are included in the supplementary material.